X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NOVARTIS AJANTA PHARMA/
NOVARTIS
 
P/E (TTM) x 28.9 392.7 7.4% View Chart
P/BV x 11.9 19.3 61.6% View Chart
Dividend Yield % 0.5 1.5 33.8%  

Financials

 AJANTA PHARMA   NOVARTIS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
NOVARTIS
Mar-16
AJANTA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,720982 175.2%   
Low Rs1,103556 198.3%   
Sales per share (Unadj.) Rs194.6252.9 76.9%  
Earnings per share (Unadj.) Rs45.262.1 72.8%  
Cash flow per share (Unadj.) Rs50.363.3 79.5%  
Dividends per share (Unadj.) Rs8.0010.00 80.0%  
Dividend yield (eoy) %0.61.3 43.6%  
Book value per share (Unadj.) Rs132.0363.6 36.3%  
Shares outstanding (eoy) m88.7731.96 277.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.0 238.5%   
Avg P/E ratio x31.212.4 252.2%  
P/CF ratio (eoy) x28.112.2 231.0%  
Price / Book Value ratio x10.72.1 505.4%  
Dividend payout %17.716.1 109.9%   
Avg Mkt Cap Rs m125,29924,580 509.8%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,5701,801 142.7%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m17,2758,083 213.7%  
Other income Rs m166829 20.1%   
Total revenues Rs m17,4428,913 195.7%   
Gross profit Rs m5,807234 2,479.6%  
Depreciation Rs m45137 1,227.8%   
Interest Rs m492 2,716.7%   
Profit before tax Rs m5,4741,025 534.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m1,460752 194.1%   
Profit after tax Rs m4,0141,986 202.1%  
Gross profit margin %33.62.9 1,160.2%  
Effective tax rate %26.773.4 36.4%   
Net profit margin %23.224.6 94.6%  
BALANCE SHEET DATA
Current assets Rs m7,63912,678 60.3%   
Current liabilities Rs m2,7152,433 111.6%   
Net working cap to sales %28.5126.7 22.5%  
Current ratio x2.85.2 54.0%  
Inventory Days Days4333 132.2%  
Debtors Days Days7922 349.8%  
Net fixed assets Rs m6,91469 9,991.0%   
Share capital Rs m177160 110.7%   
"Free" reserves Rs m11,44211,460 99.8%   
Net worth Rs m11,72111,621 100.9%   
Long term debt Rs m1490-   
Total assets Rs m14,81414,400 102.9%  
Interest coverage x112.9570.5 19.8%   
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 207.7%   
Return on assets %27.413.8 198.7%  
Return on equity %34.217.1 200.4%  
Return on capital %46.523.6 197.4%  
Exports to sales %55.10.7 7,404.9%   
Imports to sales %6.018.6 32.3%   
Exports (fob) Rs m9,52760 15,825.7%   
Imports (cif) Rs m1,0381,503 69.0%   
Fx inflow Rs m10,422186 5,594.1%   
Fx outflow Rs m1,6781,821 92.2%   
Net fx Rs m8,744-1,635 -534.9%   
CASH FLOW
From Operations Rs m3,2642,531 129.0%  
From Investments Rs m-2,093-8,270 25.3%  
From Financial Activity Rs m-1,186-386 307.4%  
Net Cashflow Rs m-15-6,125 0.2%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 2.0 77.5%  
FIIs % 7.6 1.6 475.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.5 79.1%  
Shareholders   20,968 41,647 50.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Sensex Touching New Highs, Takeaways from Acquisition of HPCL and Top Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,798 yesterday. Considering a span of one year, the benchmark index has delivered a 32% return.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS